



AGING, MEMORY, AND THE BRAIN

**Anne M. Lipton, M.D., Ph.D.
Assistant Professor of Neurology
and Psychiatry
UT-Southwestern**



NORMAL AGING AND THE BRAIN

- **Reduced brain weight and volume**
 - **Fewer neurons**
 - **Widening of sulci (grooves)**
 - **Enlargement of the ventricular system**
-



NORMAL AGING AND THE BRAIN

- **Decreased number of proteins**
 - **Decreased enzyme levels (DA & NE)**
 - **Decreased number of receptors (DA, NE, and Ach)**
 - **Sensory changes**
-



AGING AND MEMORY



STABLE MEMORY FUNCTIONS IN AGING

- **Remote memory**
 - **Crystallized abilities**
 - **Recall of verbal information**
 - **Remembering “gist” / themes**
 - **Simple Attention**
-



AGE-SENSITIVE MEMORY FUNCTIONS

- **New Learning (particularly if exceeds working memory span)**
 - **Rapid Learning**
 - **Recall of nonverbal information**
 - **Remembering details**
 - **Material requiring manipulation or multitasking**
-



MEMORY DYSFUNCTION IN ALZHEIMER'S DISEASE

- **Impaired encoding**
 - **Rapid forgetting**
 - **Recency Recall**
 - **Intrusions during recall**
 - **Impaired Recognition**
-



MEMORY IN OLD AGE VERSUS AD

- **Despite overlap, each displays a distinct pattern in memory performance**
 - **Qualitative features assist discrimination**
 - **Findings suggest different underlying processes; not a continuum**
-



MILD COGNITIVE IMPAIRMENT (MCI)

- **Memory disturbance in absence of other cognitive deficits or frank dementia**
 - **Performance on formal memory testing that falls below normal (WMS)**
 - **May = early phase of Alzheimer's (10% / yr)**
-



ALZHEIMER'S DISEASE



ALZHEIMER'S DISEASE IN TEXAS

- **280,964 people with AD in Texas alone**
 - **Prevalence - 10% increase with each decade over 65**
 - **Population is aging**
 - **Over 85, 2M in 1900, 20M in 1997, 30-40M in 2030**
 - **In 2025, -> 97% increase -> 1/2M**
-



IMPACT OF ALZHEIMER'S DISEASE ON SOCIETAL COSTS

- **Some studies report that Alzheimer's disease costs \$100 billion in the United States annually**
 - **A cost of \$35,000 per patient per year**
 - **Alzheimer's patients/families spend >\$200,000 over the remainder of the patient's life**
 - **10% to 30% of nursing home residents have Alzheimer's disease**
-



DIAGNOSTIC CRITERIA FOR ALZHEIMER'S DISEASE

- **Development of multiple cognitive deficits manifested by both**
 - **Memory impairment**
 - **One (or more) of the following cognitive disturbances: aphasia; apraxia; agnosia; disturbance in executive functioning**
 - **Significant impairment in social or occupational functioning, representing a significant decline from a previous level of functioning**
 - **Gradual onset and progressive cognitive decline**
-



DIAGNOSTIC CRITERIA FOR ALZHEIMER'S DISEASE (cont)

- **Cognitive deficits are NOT due to any of the following:**
 - **Other central nervous system conditions that cause progressive deficits in memory and cognition**
 - **Systemic conditions that are known to cause dementia**
 - **Substance-induced conditions**
 - **Deficits not occurring exclusively during the course of a delirium**
 - **Disturbance not better accounted for by another Axis I disorder**
-



THE 5 A'S OF ALZHEIMER'S DISEASE

- **Amnesia**
 - **Agnosia**
 - **Aphasia**
 - **Apraxia**
 - **Abstraction**
-



SYMPTOMS OF ALZHEIMER'S DISEASE

- **Gradual memory loss**
 - **Decline in ability to perform routine tasks**
 - **Disorientation**
 - **Poor judgment**
 - **Language (“empty speech”)**
 - **Apathy/poor motivation**
-



MEMORY LOSS IN ALZHEIMER'S DISEASE

- **“Memory leads the way”**
 - **Memory worst and first**
 - **More problems with new (recent) info than with old (remote)**
-



DIAGNOSIS OF ALZHEIMER'S DISEASE

- **IMPORTANT - IT'S TREATABLE!**
 - reversible conditions (depression, thyroid, B12)
 - cholinesterase inhibitors
 - other: NSAIDS, estrogen, chol Rx, BP Rx, stroke Rx
 - **IMPORTANT - Rx is not only treatment**
 - **What is most important in diagnosing AD?**
-



DIAGNOSTIC WORK-UP FOR DEMENTIA

- **Diagnostic Interview**
 - **Exam, including Neurologic and Mental Status exam**
 - **Labs(CBC,chemistries,LFTs,TSH,RPR/MH A-TP,Vit B12,cholesterol)**
 - **Neuroimaging**
 - **Neuropsychological evaluation**
 - **Language evaluation, LP, genetics - specialist referral**
-



NEUROBEHAVIORAL HISTORY AND EXAM

- **Attention**
 - **Visuospatial**
 - **Language**
 - **Memory**
 - **Executive Functions**
 - **Personality/Behavior**
-



STAGES OF ALZHEIMER'S DISEASE

- **Stage I (1-3 y) - poor recent memory, may get lost, empty speech, apathetic**
 - **Stage II - (2-10 y) poor recent and remote memory, gets lost easily, empty speech, poor comprehension, agitation, delusions**
 - **Stage III - very poor thinking, repeats words, limb rigidity, incontinence**
-



PATHOPHYSIOLOGIC MECHANISMS IN ALZHEIMER'S DISEASE

- **Cholinergic mechanisms**
 - **Neuritic plaques**
 - **Beta-amyloid**
 - **Neurofibrillary tangles**
 - **Free-radical mechanisms**
 - **Inflammatory mechanisms**
 - **Cholesterol/statins?**
-



TREATMENT OF ALZHEIMER'S DISEASE

- **Cholinesterase inhibitors**
 - **Vitamin E**
 - **Hormone replacement**
 - **NSAIDS**
 - **Herbal**
 - **“Amyloid Vaccine”?! , “ACE” inhibitors**
 - **Antidepressants/other psychiatric**
 - **Behavior/environment modification**
-



CHOLINESTERASE INHIBITORS:

- **Approved for use in mild-moderate AD (MMSE ~10-26)**
 - **GI side effects**
 - **Expected outcome of therapy - to SLOW decline**
 - **ADL's, Behavior, Cognition improved up to 2 yrs vs. placebo**
-



VITAMIN E

- **Disease-modifying agent**
 - **Benefits proven in double-blind study (Sano et al., 1997)**
 - **Vitamin E 1000 International Units BID**
 - **Blood thinner**
-



ESTROGEN REPLACEMENT THERAPY

- **Retrospective studies have shown decreased risk of AD**
 - **Prospective study (Mulnard et al., 2000) showed no benefit in women with AD**
 - **BUT, possible preventive effect still under study**
-



ANTI-INFLAMMATORY MEDICATIONS

- **Retrospective study (Stewart et al., 1997) showed decreased risk with NSAIDS (but not aspirin)**
 - **Prospective study of COX-2 inhibitors ongoing**
 - **Caution: bleeding risk**
-



GINGKO BILOBA

- **Blood thinner**
 - **Benefit unproven - \$15M study**
 - **120-240 mg daily**
-



“AMYLOID VACCINE”

- **Mouse model of AD**
 - **Plaques could be prevented or reversed in mice injected with amyloid (Schenk et al., July 1999)**
 - **Human safety trials ongoing in UK**
-



AMYLOID CLEAVAGE ENZYME INHIBITORS

- **Amyloid precursor protein**
 - **cleaved at different sites by different enzymes**
 - **-> long or short forms of amyloid**
 - **Longer amyloid is “sticky” -> plaques**
-



BEHAVIOR-MODIFYING MEDICATIONS

- **70-90% of patients with dementia**
 - **Multiple medications can treat these symptoms**
 - **Behavior/environment modification**
-



HUMAN ADULT BRAIN CAN CREATE NEW CELLS

- **TRUE**
 - **or**
 - **FALSE?**
-



WHAT'S SO SPECIAL ABOUT THE BRAIN?

- **SPECIALIZATION (DIFFERENTIATION)**
 - **100 BILLION NEURONS**
 - **60-100 TRILLION SYNAPSES
(connections)**
-



THE REASON FOR RECESS

- **Stimulating environment**
 - **Running wheel**
 - **Stress**
 - **Depression**
-



RESOURCES FOR TEACHERS

- <http://lshome.utsa.edu/programs/Neurobiology/nlca/NLCA.htm>
 - Society for Neurosci & NABT
 - <http://www.sfn.org/cnl/>
 - Society for Neuroscience
-



RESOURCES FOR TEACHERS II

- <http://www.aan.com/public/lessonplans/>
 - <http://faculty.washington.edu/chudler/neurok.html>
 - <http://faculty.washington.edu/chudler/experi.html>
-